Wal-Yan Respiratory Research Centre, Telethon Kids Institute, Perth Children's Hospital, Nedlands, Australia.
Curtin School of Allied Health, Faculty of Health Sciences, Bentley, Australia.
Pediatr Pulmonol. 2023 Nov;58(11):3122-3132. doi: 10.1002/ppul.26632. Epub 2023 Aug 4.
The European Respiratory Society Oscillometry Taskforce identified that clinical correlates of bronchodilator responses are needed to advance oscillometry in clinical practice. The understanding of bronchodilator-induced oscillometry changes in preterm lung disease is poor. Here we describe a comparison of bronchodilator assessments performed using oscillometry and spirometry in a population born very preterm and explore the relationship between bronchodilator-induced changes in respiratory function and clinical outcomes.
Participants aged 6-23 born ≤32 (N = 288; 132 with bronchopulmonary dysplasia) and ≥37 weeks' gestation (N = 76, term-born controls) performed spirometry and oscillometry. A significant bronchodilator response (BDR) to 400 μg salbutamol was classified according to published criteria.
A BDR was identified in 30.9% (n = 85) of preterm-born individuals via spirometry and/or oscillometry, with poor agreement between spirometry and oscillometry definitions (k = 0.26; 95% confidence interval [CI] 0.18-0.40, p < .001). Those born preterm with a BDR by oscillometry but not spirometry had increased wheeze (33% vs. 11%, p = .010) and baseline resistance (Rrs z-score mean difference (MD) = 0.86, 95% CI 0.07-1.65, p = .025), but similar baseline spirometry to the group without a BDR (forced expiratory volume in 1 s [FEV ] z-score MD = -0.01, 95% CI -0.66 to 0.68, p > .999). Oscillometry was more feasible than spirometry (95% success rate vs. 85% (FEV ), 69% (forced vital capacity) success rate, p < .001), however being born preterm did not affect test feasibility.
In the preterm population, oscillometry is a feasible and clinically useful supportive test to assess the airway response to inhaled salbutamol. Changes measured by oscillometry reflect related but distinct physiological changes to those measured by spirometry, and thus these tests should not be used interchangeably.
欧洲呼吸学会振荡测量任务组确定,需要临床相关的支气管扩张剂反应来推进临床实践中的振荡测量。早产儿肺部疾病中支气管扩张剂诱导的振荡测量变化的理解很差。在这里,我们描述了使用振荡测量法和肺活量计对非常早产儿人群进行支气管扩张剂评估的比较,并探讨了呼吸功能的支气管扩张剂诱导变化与临床结果之间的关系。
年龄在 6-23 岁,胎龄≤32 周(N=288;132 例患有支气管肺发育不良)和≥37 周(N=76 例,足月出生对照组)的参与者进行了肺活量计和振荡测量。根据已发表的标准,将 400μg 沙丁胺醇的显著支气管扩张剂反应(BDR)进行分类。
通过肺活量计和/或振荡测量法,在 30.9%(n=85)的早产儿中确定了 BDR,肺活量计和振荡测量法的定义之间的一致性较差(k=0.26;95%置信区间 [CI] 0.18-0.40,p<0.001)。通过振荡测量法而非肺活量计确定的早产儿中,BDR 组喘息(33% vs. 11%,p=0.010)和基线阻力(Rrs z 分数平均差异(MD)=0.86,95%CI 0.07-1.65,p=0.025)更高,但与没有 BDR 的组相比,基线肺活量计相似(FEV 1 z 分数 MD=-0.01,95%CI-0.66 至 0.68,p>0.999)。与肺活量计相比,振荡测量法更可行(95%成功率与 85%(FEV 1)、69%(用力肺活量)成功率相比,p<0.001),但是胎龄早产不会影响测试可行性。
在早产儿人群中,振荡测量法是一种可行且具有临床意义的支持性测试,可以评估吸入沙丁胺醇后的气道反应。通过振荡测量法测量的变化反映了与通过肺活量计测量的变化相关但不同的生理变化,因此这些测试不应互换使用。